Osavampator not checked

Neurocrine Biosciences · TAK-653 · NBI-1065845

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
8 in total · 5 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Major Depressive Disorder (5 trials)
Main trialPhase 3
“The study will evaluate the efficacy of osavampator (previously NBI-1065845) compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.”In the company’s words, NCT06786624 on ClinicalTrials.gov
Other names
TAK-653 · NBI-1065845

Other drugs for Major Depressive Disorder

All 36 drugs for Major Depressive Disorder

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2027 Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2027 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2027 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting Jul 2028 A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 3Recruiting May 2029 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Phase 2Completed 10 Jan 2024 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Phase 1Completed 11 Sep 2017 TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants
Phase 1Completed 15 May 2019 A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Osavampator

Following is part of Solo: you see every change to Osavampator the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in